Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Decitabine (DB01262)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00002980Decitabine in Treating Patients With Melanoma or Other Advanced CancerTreatment
NCT00114257Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersTreatment